肾病药物市场（2026—2031）
肾病药物市场规模预计由2026年的424亿美元增至2031年的646.2亿美元，预测期复合年增长率为8.75%。北美保持最大市场地位，亚太地区增长最快。
市场研究正文
规模、增长、细分、驱动因素与关键问题
当前质量分 100.00，审核状态 accepted。结构化字段已按 RoboInd 内容层级组织。
核心结论
肾病药物市场规模预计由2026年的424亿美元增至2031年的646.2亿美元，预测期复合年增长率为8.75%。北美保持最大市场地位，亚太地区增长最快。
市场走势
结构化指标
| 指标 | 年份 | 数值 | 性质 |
|---|---|---|---|
| 复合年增长率 | 2031 | 8.75% | 机构预测 |
| 市场规模 | 2026 | USD 42.4 billion | 机构预测 |
| 市场规模 | 2031 | USD 64.62 billion | 机构预测 |
细分市场份额
市场结构
| 维度 | 细分项 | 年份 | 份额 |
|---|---|---|---|
| distribution_channel | retail pharmacies | 2025 | 42.700% |
| drug_class | RAS inhibitors | 2025 | 31.800% |
| indication | CKD | 2025 | 38.500% |
| route_of_administration | oral formulations | 2025 | 72.400% |
关键结论
- distribution_channel 维度中，retail pharmacies 在 2025 年的公开份额为 42.7%。
- drug_class 维度中，RAS inhibitors 在 2025 年的公开份额为 31.8%。
- indication 维度中，CKD 在 2025 年的公开份额为 38.5%。
- route_of_administration 维度中，oral formulations 在 2025 年的公开份额为 72.4%。
主要参与者
- Bayer AG
- Novartis AG
- Pfizer Inc.
- F. Hoffmann-La Roche Ltd
- AbbVie Inc.
增长驱动因素
| 因素 | 影响 CAGR | 地区相关性 | 影响周期 |
|---|---|---|---|
| Rising Chronic Kidney Disease and End-Stage Renal Disease Burden | +2.500% | Global | Long term (≥ 4 years) |
| Expansion of Renal-Protective SGLT2 Inhibitor Use Beyond Diabetes | +1.800% | Global, led by North America, EU, APAC | Medium term (2-4 years) |
| Earlier Detection Through eGFR and Albuminuria Screening | +0.900% | Global, strongest in high-income regions | Medium term (2-4 years) |
| Aging, Diabetes, Hypertension and Obesity Comorbidity Load | +1.400% | Global, concentrated in APAC and North America | Long term (≥ 4 years) |
| Increasing Investment in Precision Nephrology and Rare Kidney Disease Therapies | +0.700% | North America and Europe | Medium term (2-4 years) |
| Digitally Enabled Home and Outpatient Medication Management | +0.400% | North America, Europe, and core APAC markets | Short term (≤ 2 years) |
市场制约因素
| 因素 | 影响 CAGR | 地区相关性 | 影响周期 |
|---|---|---|---|
| High Cost and Reimbursement Friction for Novel Renal Therapies | -1.000% | Global, most acute in LMICs and ESRD bundled-payment markets | Medium term (2-4 years) |
| Long and Complex Kidney-Outcome Trial Requirements | -0.800% | Global | Long term (≥ 4 years) |
| Renal-Dose Errors and Medication-Management Complexity | -0.500% | Global | Short term (≤ 2 years) |
| Late Diagnosis, Low Awareness and Uneven Specialist Access | -0.600% | APAC, Middle East and Africa, and South America | Long term (≥ 4 years) |
报告关注的关键问题
What is driving demand for nephrology drugs?
CKD affected 788 million adults globally in 2023, while diagnosis gaps and metabolic risk factors continue to widen treatment demand.
Which nephrology drug class is growing fastest?
SGLT2 inhibitors are forecast to grow at a 10.8% CAGR through 2031, supported by KDIGO guidance for eligible adults with CKD
Why are SGLT2 inhibitors used in chronic kidney disease?
KDIGO recommends SGLT2 inhibitors for eligible adults with CKD regardless of diabetes status, widening their potential role in renal care.
Which region is expanding fastest for renal therapies?
Asia-Pacific is projected to grow at a 10.9% CAGR through 2031, supported by its large CKD burden and improving access infrastructure.
What limits access to newer kidney medicines?
High therapy costs and dialysis payment structures can restrict uptake, particularly in lower-income countries and bundled-payment settings.
Why are specialty pharmacies important in kidney care?
Specialty pharmacies support medicines that require monitoring, cold-chain logistics, restricted distribution, and patient services.
市场概览
- 增长最快市场：亚太地区
- 最大市场：北美
- 市场集中度：中等
查看来源：Mordor Intelligence